Show simple item record

dc.contributor.authorAzizi, Alexander
dc.contributor.authorPillai, Manon
dc.contributor.authorThistlethwaite, Fiona C
dc.date.accessioned2019-09-11T09:09:19Z
dc.date.available2019-09-11T09:09:19Z
dc.date.issued2019en
dc.identifier.citationAzizi AA, Pillai M, Thistlethwaite FC. T-cell receptor and chimeric antigen receptor in solid cancers: current landscape, preclinical data and insight into future developments. Curr Opin Oncol. 2019;31(5):430-8.en
dc.identifier.pmid31335828en
dc.identifier.doi10.1097/CCO.0000000000000562en
dc.identifier.urihttp://hdl.handle.net/10541/622041
dc.description.abstractPURPOSE OF REVIEW: The remarkable and durable clinical responses seen in certain solid tumours using checkpoint inhibitors and in haematological malignancies using chimeric antigen receptor (CAR) T therapy have led to great interest in the possibility of using engineered T-cell receptor (TCR) and CAR T therapies to treat solid tumours. RECENT FINDINGS: In this article, we focus on the published clinical data for engineered TCR and CAR T therapy in solid tumours and recent preclinical work to explore how these therapies may develop and improvE We discuss recent approaches in target selection, encouraging epitope spreading and replicative capacity, CAR activation, T-cell trafficking, survival in the immunosuppressive microenvironment, universal T-cell therapies, manufacturing processes and managing toxicity. SUMMARY: In haematological malignancies, CAR T treatments have shown remarkable clinical responseS Engineered TCR and CAR therapies demonstrate responses in numerous preclinical models of solid tumours and have shown objective clinical responses in select solid tumour types. It is anticipated that the integration of efficacious changes to the T-cell products from disparate preclinical experiments will increase the ability of T-cell therapies to overcome the challenges of treating solid tumours and note that healthcare facilities will need to adapt to deliver these treatments.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1097/CCO.0000000000000562en
dc.titleT-cell receptor and chimeric antigen receptor in solid cancers: current landscape, preclinical data and insight into future developmentsen
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchesteren
dc.identifier.journalCurrent Opinion in Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record